Biediger, Ronald,Gundlach, Iv,Market, Robert,Savage, Michael,Vanderslice, Peter
申请号：
NZ74660511
公开号：
NZ746605A
申请日:
2011.11.16
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
Provided are N,N-disubstituted amide, carbamate, urea and sulphonamide compounds of the general formula (I), wherein the variables are as described in the specification. Examples of the compounds include methyl (6S,10S)-10-(1,3-benzodioxol-5-yl)-6-butyl-3,8-dioxo-1-(2-thienyl)-2-(2-thienylmethyl)-4-oxa-2,7,9-triazadodecan-12-oate and 2-[{ 2-[bis(2-thienylmethyl)sulfamoyl]ethyl} (methyl)amino]-N,N-bis(2-thienylmethyl)acetamide. The compounds are integrin agonists that enhance the binding of cells to integrin ligands. Further provided is a method of enhancing the retention of exogenously-introduced cells at an in vivo target site and a method for treating damaged or diseased vascular tissue comprising treating the cells with the compounds and introducing them to an in vivo target site.
